Global Sprycel Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sprycel Market Research Report 2024
Dasatinib, sold under the brand name Sprycel, is a chemotherapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL).
According to Mr Accuracy reports new survey, global Sprycel market is projected to reach US$ 514.6 million in 2029, increasing from US$ 296 million in 2022, with the CAGR of 8.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sprycel market research.
Sprycel received regulatory approvals for use in CML and Ph+ ALL in various countries, expanding its market reach and availability.
Recommendations from medical societies and clinical guidelines regarding the use of Sprycel in specific patient populations can influence its demand.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sprycel market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bristol-Myers Squibb
LUCIUS Pharma
Segment by Type
20mg
50mg
70mg
CML
ALL
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Sprycel report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Sprycel market is projected to reach US$ 514.6 million in 2029, increasing from US$ 296 million in 2022, with the CAGR of 8.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sprycel market research.
Sprycel received regulatory approvals for use in CML and Ph+ ALL in various countries, expanding its market reach and availability.
Recommendations from medical societies and clinical guidelines regarding the use of Sprycel in specific patient populations can influence its demand.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Sprycel market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bristol-Myers Squibb
LUCIUS Pharma
Segment by Type
20mg
50mg
70mg
Segment by Application
CML
ALL
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Sprycel report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source